Terence H Rabbitts

List of Publications by Year
in descending order

74 papers	4,302 citations	109137 35 h-index	110170 64 g-index
79 all docs	79 docs citations	79 times ranked	4908 citing authors

#	Article	IF	Citations
1	A Cell-based Screening Method Using an Intracellular Antibody for Discovering Small Molecules Targeting Hard-to-drug Proteins. Bio-protocol, 2022, 12, e4324.	0.2	1
2	Pan RAS-binding compounds selected from a chemical library by inhibiting interaction between RAS and a reduced affinity intracellular antibody. Scientific Reports, 2021, 11, 1712.	1.6	6
3	A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. Science Advances, 2021, 7, .	4.7	8
4	A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. Scientific Reports, 2021, 11, 10617.	1.6	28
5	Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins. Scientific Reports, 2021, 11, 10475.	1.6	6
6	Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds. Journal of Immunological Methods, 2021, 494, 113051.	0.6	2
7	An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells. Leukemia Research, 2021, 108, 106626.	0.4	6
8	Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science, 2021, 374, 472-478.	6.0	228
9	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. Antiviral Research, 2021, 194, 105147.	1.9	11
10	Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol. Communications Biology, 2020, 3, 342.	2.0	14
11	A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. Nature Communications, 2020, 11, 3233.	5.8	68
12	Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats. MAbs, 2020, 12, 1752529.	2.6	19
13	Immunopolymer Lipid Nanoparticles for Delivery of Macromolecules to Antigen-Expressing Cells. ACS Applied Bio Materials, 2020, 3, 8481-8495.	2.3	4
14	Selection and Characterization of a Nanobody Biosensor of GTP-Bound RHO Activities. Antibodies, 2019, 8, 8.	1.2	26
15	Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2545-2550.	3.3	96
16	KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe. Nature Communications, 2019, 10, 2607.	5.8	66
17	Cancer cell killing by target antigen engagement with engineered complementary intracellular antibody single domains fused to pro-caspase3. Scientific Reports, 2019, 9, 8553.	1.6	6
18	Surfaceome interrogation using an RNA-seq approach highlights leukemia initiating cell biomarkers in an LMO2 T cell transgenic model. Scientific Reports, 2019, 9, 5760.	1.6	8

#	Article	IF	Citations
19	Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves. ACS Applied Materials & Interfaces, 2019, 11, 10481-10491.	4.0	32
20	Bioluminescence Resonance Energy Transfer 2 (BRET2)â€Based RAS Biosensors to Characterize RAS Inhibitors. Current Protocols in Cell Biology, 2019, 83, e83.	2.3	8
21	Cloning, purification and structure determination of the HIV integrase-binding domain of lens epithelium-derived growth factor. Acta Crystallographica Section F, Structural Biology Communications, 2018, 74, 143-149.	0.4	3
22	BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. ELife, 2018, 7, .	2.8	41
23	Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment. Nature Communications, 2018, 9, 3169.	5.8	100
24	A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS. Scientific Reports, 2017, 7, 44899.	1.6	4
25	Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein. Scientific Reports, 2017, 7, 16869.	1.6	8
26	Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange. Nature Communications, 2017, 8, 16111.	5.8	77
27	Abstract LB-068: From intracellular antibody fragments to small molecule inhibitors of mutant KRAS. , 2017, , .		0
28	LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma. Clinics in Oncology, 2017, 2, 1183.	0.0	0
29	Exploring the surfaceome of Ewing sarcoma identifies a new and unique therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3603-3608.	3.3	42
30	LMO2 at 25 years: a paradigm of chromosomal translocation proteins. Open Biology, 2015, 5, 150062.	1.5	58
31	Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes. Molecular Immunology, 2014, 58, 160-168.	1.0	41
32	Intracellular antibody capture: A molecular biology approach to inhibitors of proteinâ€"protein interactions. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1970-1976.	1.1	10
33	ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood, 2014, 124, 3738-3747.	0.6	198
34	Single Domain Antibody Fragments as Drug Surrogates Targeting Proteinâ€"Protein Interactions inside Cells. Antibodies, 2013, 2, 306-320.	1.2	6
35	Nonreciprocal chromosomal translocations in renal cancer involve multiple DSBs and NHEJ associated with breakpoint inversion but not necessarily with transcription. Genes Chromosomes and Cancer, 2013, 52, 402-409.	1.5	10
36	Requirement for Lyl1 in a model of Lmo2-driven early T-cell precursor ALL. Blood, 2013, 122, 2093-2103.	0.6	62

#	Article	IF	Citations
37	Intracellular Antibody Capture (IAC) Methods for Single Domain Antibodies. Methods in Molecular Biology, 2012, 911, 151-173.	0.4	7
38	Single Domain Intracellular Antibodies from Diverse Libraries. Journal of Biological Chemistry, 2011, 286, 3707-3716.	1.6	35
39	Intracellular antibodies and cancer: New technologies offer therapeutic opportunities. BioEssays, 2010, 32, 589-598.	1.2	38
40	Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture. Nature Protocols, 2010, 5, 67-92.	5.5	38
41	The <i>Lmo2</i> Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal. Science, 2010, 327, 879-883.	6.0	201
42	PCRPi: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces. Nucleic Acids Research, 2010, 38, e86-e86.	6.5	70
43	Selection of complementary single-variable domains for building monoclonal antibodies to native proteins. Nucleic Acids Research, 2009, 37, e41-e41.	6.5	8
44	Targeting LMO2 with a Peptide Aptamer Establishes a Necessary Function in Overt T-Cell Neoplasia. Cancer Research, 2009, 69, 4784-4790.	0.4	36
45	Commonality but Diversity in Cancer Gene Fusions. Cell, 2009, 137, 391-395.	13.5	61
46	Functional Intracellular Antibody Fragments Do Not Require Invariant Intra-domain Disulfide Bonds. Journal of Molecular Biology, 2008, 376, 749-757.	2.0	34
47	Interfering with protein-protein interactions: Potential for cancer therapy. Cell Cycle, 2008, 7, 1569-1574.	1.3	28
48	Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO Journal, 2007, 26, 3250-3259.	3.5	141
49	ETV6: Its Role in Mouse Development and Leukaemogenesis Using Knock-Out and Knock-In Models.. Blood, 2007, 110, 461-461.	0.6	1
50	Interrogation of genomes by molecular copy-number counting (MCC). Nature Methods, 2006, 3, 447-453.	9.0	38
51	Activation of the T-Cell OncogeneLMO2after Gene Therapy for X-Linked Severe Combined Immunodeficiency. New England Journal of Medicine, 2004, 350, 913-922.	13.9	257
52	Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EMBO Journal, 2003, 22, 1025-1035.	3.5	120
53	Chromosomal translocation products engender new intracellular therapeutic technologies. Nature Medicine, 2003, 9, 383-386.	15.2	41
54	Single Domain Intracellular Antibodies: A Minimal Fragment For Direct In Vivo Selection of Antigen-specific Intrabodies. Journal of Molecular Biology, 2003, 331, 1109-1120.	2.0	107

#	Article	IF	Citations
55	Intracellular antibodies and challenges facing their use as therapeutic agents. Trends in Molecular Medicine, 2003, 9, 390-396.	3.5	87
56	De novo production of diverse intracellular antibody libraries. Nucleic Acids Research, 2003, 31, 23e-23.	6.5	36
57	The LMO2 T-Cell Oncogene Is Activated via Chromosomal Translocations or Retroviral Insertion during Gene Therapy but Has No Mandatory Role in Normal T-Cell Development. Molecular and Cellular Biology, 2003, 23, 9003-9013.	1.1	123
58	Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. Journal of Molecular Biology, 2002, 317, 85-94.	2.0	87
59	The LIM-domain protein Lmo2 is a key regulator of tumour angiogenesis: a new anti-angiogenesis drug target. Oncogene, 2002, 21, 1309-1315.	2.6	45
60	T cell tumorigenesis in Lmo2 transgenic mice is independent of V-D-J recombinase activity. Oncogene, 2001, 20, 4412-4415.	2.6	10
61	Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene, 2001, 20, 5763-5777.	2.6	38
62	Masked antisense: a molecular configuration for discriminating similar RNA targets. EMBO Reports, 2000, 1, 59-64.	2.0	6
63	Of methods and mapping. Nature Medicine, 1999, 5, 24-25.	15.2	1
64	Characterization of the Lmo4 gene encoding a LIM-only protein: genomic organization and comparative chromosomal mapping. Mammalian Genome, 1999, 10, 1089-1094.	1.0	13
65	Chromosomal breakpoints hit the spot. Nature Medicine, 1997, 3, 496-497.	15.2	4
66	A Complete Map of the Human Immunoglobulin V_H Locus. Annals of the New York Academy of Sciences, 1995, 764, 43-46.	1.8	25
67	A map of the human immunoglobulin VH locus completed by analysis of the telomeric region of chromosome 14q. Nature Genetics, 1994, 7, 162-168.	9.4	247
68	The Oncogenic Cysteine-rich LIM domain protein Rbtn2 is essential for erythroid development. Cell, 1994, 78, 45-57.	13.5	582
69	Immunoglobulin VH-T cell receptor CÎ± fusion mRNA resulting from chromosome inversion include the T cell-associated 5â€² exon ET. European Journal of Immunology, 1992, 22, 2745-2748.	1.6	1
70	Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell, 1991, 67, 641-644.	13.5	281
71	Unusual forms of T cell Î³ mRNA in a human T cell leukemia cell line: Implications for Î³ gene expression. European Journal of Immunology, 1987, 17, 1729-1736.	1.6	39
72	Chromosome translocation can occur on either side of the c-myc oncogene in Burkitt lymphoma cells. Nature, 1984, 308, 286-288.	13.7	102

#	Article	IF	Citations
73	Potential Z-DNA between exons of human secreted and membrane immunoglobulin heavy-chain Î¼-gene. Biochemical Society Transactions, 1984, 12, 863-863.	1.6	0
74	The LMO2 Master Gene; Its Role as a Transcription Regulator Determining Cell Fate in Leukemogenesis and in Hematopoiesis. , 0, , 483-495.		0